Browse studies

Find your next paid study

27,332 recruiting studies available now

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy …

Pancreas CancerOligometastatic

Estimated

~$50 – $1,500

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT06593431

Phase 2

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Clinical T1-2N0 ER+ Her2- Breast Cancer With Ultrasound Detected Nodal Metastases

The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy pr…

Breast CancerAxillary Nodal DiseaseFemale Breast Cancer+3 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Alice ChungNCT06092892

Phase 2

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma; a Phase II Trial PANcreas CAncer RaDIofrequeNcy AbLation

The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherap…

Pancreatic Ductal Adenocarcinoma

Estimated

~$75 – $2,000

Actual pay is set by the research site.

The University of Texas Health Science Center, HoustonNCT06831136

Phase 1

A Pilot Study of Duffy Null-Specific Dose Modifications for Individuals With Duffy Null Phenotype Receiving Standard of Care Systemic Anti-Cancer Therapies

This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null spec…

Multiple MyelomaTriple Negative Breast CancerDuffy Blood Group, Chemokine Receptor Gene Mutation+1 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Andrew Hantel, MDNCT07341867

Palynziq and PKU: Treatment Impacts on Diet Quality, Neurological Health, Nutritional Status, and the Metabolome

Phenylketonuria (PKU) is an inherited metabolic disorder that impairs the metabolism of the essential amino acid phenylalanine (Phe). Without stringent dietary…

Phenylketonurias

Estimated

~$10 – $750

Actual pay is set by the research site.

Emory UniversityNCT04404530

Optical Coherence Tomography Angiography in Neovascular Age-related Macular Degeneration

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. diagnose the presence of new blood ves…

Neovascular (Wet) Age-related Macular Degeneration (AMD)

Estimated

~$10 – $750

Actual pay is set by the research site.

Oregon Health and Science UniversityNCT02253030

Phase 1

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well E…

Advanced Solid TumorsMSI-H or dMMR Advanced Solid TumorsMSI-H/dMMR Gastric Cancer+4 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Eikon Therapeutics

Phase 1

A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation

Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.

Solid Tumors

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Quanta TherapeuticsNCT06227377

Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Low-Dose Post-Transplant Cyclophosphamide for Prophylaxis of Graft-versus-Host Disease in Hematological Malignancies

This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophyla…

Graft-versus-Host Disease (GVHD)Hematologic MalignanciesAllogeneic Stem Cell Transplantation

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Milton S. Hershey Medical CenterNCT06926595

Patient-Centered Approach for Treatment Decisions in Mitral Valve Prolapse (PRIMARY SDM)

This is a qualitative and quantitative study that seeks to obtain information from patients with degenerative mitral valve prolapse and providers regarding fac…

Mitral Valve Prolapse

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Northwell HealthNCT06738537

Phase 1

A First-in-human, Open-label (Part 1), Randomized (Part 2), Phase I/IIa Trial to Study Safety and Tolerability of Multiple Rising Intravitreal Doses of BI 3812465 in Patients With Center-involved Diabetic Macular Edema

This study is open to adults with diabetic macular edema that involves the center of the eye. The purpose of this study is to find out how well different doses…

Diabetic Macular Edema

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Boehringer IngelheimNCT07553429

Phase 3

Ice Compress: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy

This phase III trial compares the effect of 3 study approaches in preventing chemotherapy-induced peripheral neuropathy: 1) cryocompression, 2) continuous comp…

Malignant Solid Neoplasm

Estimated

~$50 – $2,250

Actual pay is set by the research site.

SWOG Cancer Research NetworkNCT05642611